← Human Trials & Peer-Reviewed Studies

Head circumference and body proportions before and during growth hormone treatment in short children who were born small for gestational age.

Plain-language guide to PMID 15342839 (2004): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID
15342839
Journal
Pediatrics
Year
2004
Study type
Randomized Controlled Trial
Authors
Arends NJ et al. (3 authors)
DOI
10.1542/peds.2003-0152-L

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Although short children who were born small for gestational age (SGA) seem to have normal body proportions, objective data both before and during growth hormone (GH) treatment are very limited.

Therefore, the researchers investigated in a large group of short children who were born SGA the effects of GH treatment versus no treatment on head circumference (HC) and body proportions.

Who Took Part

By PubMed's age tags, the people studied were young children and children, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

Height; weight; HC; sitting height; armspan; and hand, tibial, and foot size were measured and expressed as standard deviation score (SDS) adjusting for gender and age.

What Was Measured

Topics PubMed links to this paper include Body Constitution, Body Height, Growth Disorders, Head, Human Growth Hormone and Infant, Small for Gestational Age.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (Pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.